CENCORA DL-,01/ US03073E1055 /
| 14/05/2024 16:08:07 | Chg. -2.450 | Volume | Bid22:00:00 | Ask22:00:00 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 206.100EUR | -1.17% | 47 Turnover: 9,658.100 |
204.550Bid Size: 48 | 205.500Ask Size: 48 | 40.91 bill.EUR | - | - |
GlobeNewswire
13/05
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
09/05
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...
GlobeNewswire
29/04
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...
GlobeNewswire
17/04
2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners
GlobeNewswire
22/03
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...
GlobeNewswire
18/03
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
GlobeNewswire
14/02
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire
23/01
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...
GlobeNewswire
22/12/2023
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...
GlobeNewswire
19/12/2023
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...
GlobeNewswire
27/11/2023
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path For...
GlobeNewswire
14/11/2023
Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior V...
GlobeNewswire
01/11/2023
Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (IN...
GlobeNewswire
21/09/2023
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
